Challenges in the diagnosis and treatment of pediatric bipolar depression by Chang, Kiki
here has been great public and academic inter-
est in the diagnosis and treatment of bipolar disorders
(BD) in children and adolescents over the past decade,
originally in the US but now extending internationally.
Thus, in the US in the past decade, diagnoses of BD in
children under 18 years old have risen 4000% in the com-
munity.
1Whether this increase is due to increased recog-
nition,increased incidence,or overdiagnosis is not clear.
However,it is becoming clear that BD begins in child-
hood 50% to 66% of the time.
2,3 Therefore, if the inci-
dence of BD (I or II) in adults is 4%,
4 then there are at
least 1 to 2 million children in the US alone with BD or
the beginning manifestations of the disorder.A recent
study comparing age at onset of BD in a US population
found that 30% of adults with BD in the Netherlands and
Germany had childhood/adolescent onset.
5Thus,while
possibly fewer than in the US,there are also likely great
numbers of youth in Europe with BD.
Much of the interest in pediatric BD has focused on the
unique manifestation of mania in younger populations.
Academic controversy has centered around the role of
extreme irritability in pediatric mania:whether it can be
a proxy for euphoria
6;whether Diagnostic and Statistical
Manual of Mental Disorders (DSM)-IV criteria can be
used in children under 12;and whether children with BD
eventually become adults with DSM-IV-defined BD.
7
Depression is often overlooked,both as a topic and as a
clinical reality,in these children.If BD is indeed so preva-
lent in children in the US and internationally, then
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There has been great public and academic interest in the
diagnosis and treatment of bipolar disorders (BD) in chil-
dren and adolescents over the past decade, originally in
the US, but now extending internationally. Much of the
interest in pediatric BD has focused on the unique mani-
festation of mania in younger populations. Depression is
often overlooked, both as a topic, and as a clinical reality,
in these children. While it is becoming clear that adults
with BD spend the majority of their symptomatic time in
depressive rather than manic episodes, less is known
about the pediatric experience of bipolar depression.
However, children and adolescents with BD clearly do
experience significant depressive symptoms as well as
depressive episodes, and therefore early recognition and
treatment is necessary. This review addresses what is
known about the prevalence, presentation, and treatment
of depressive symptoms and episodes in youth with BD,
and includes a discussion about the recognition and treat-
ment of bipolar depressive episodes that occur before the
first manic episode.
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:73-80.depressive symptoms and episodes in pediatric BD
deserve much greater study.This review will address what
is known about the prevalence,presentation,and treat-
ment of depressive symptoms and episodes in youth with
BD and include a discussion about the recognition and
treatment of bipolar depressive episodes before the first
manic episode.
Bipolar depression episodes in 
children and adolescents
Adults with BD spend approximately 9% of their time
in manic or hypomanic episodes, whereas they spend
32% of the time in depressive episodes.
8 Children and
adolescents with BD clearly experience significant
depressive symptoms as well as depressive episodes.
9
However,the phenomenon of depression is less studied
in pediatric BD.In a phenomenological study of 438 chil-
dren and adolescents with bipolar spectrum disorders,
53% had a history of a major depressive episode.
10
Suicidal thoughts and behaviors were common as well,
with 76% having past suicidal ideation,and 31% having
made a prior suicide attempt.Thus,depressive symptoms
are common in youth with BD.It is not clear if children
with BD are commonly misdiagnosed with unipolar
depression,but this phenomenon is common in adults.
11
It should also be noted that irritability is commonly a
presenting symptom of depression, rather than only
mania,in children.Thus,the DSM-IV allows for the pre-
dominant mood to be irritability or dysphoria for chil-
dren to meet criteria for a depressive episode.Irritability
is a common symptom in children with BD,even outside
a clearly established manic episode.
12,13 Therefore, it is
possible that a certain portion of irritability in children
with BD stems from a more depressive etiology.This is
important to remember,in that,much as adults with BD
are often misdiagnosed with unipolar depression,
11 chil-
dren with BD should not have their symptoms of irri-
tability misdiagnosed as mania if they are truly stemming
from depression.
Finally,mixed episodes occur frequently in pediatric BD.
14
In adults,these episodes have been thought to be more dif-
ficult to treat than “pure”mood episodes,and also carry
the highest risk of suicide attempts.
15,16 Similarly,in a pedi-
atric BD cohort,mixed episodes were one predictor of sui-
cide attempt.
17Thus,depressive symptoms may also occur
within the context of mania symptoms in children, and
therefore such children should also be carefully assessed
for potential mixed episodes.
There are several reasons why such depressive episodes
and symptoms in children with BD may be missed by clin-
icians.Foremost,manic symptoms usually are what bring
the child into the office, including symptoms of high
energy,impulsivity,recklessness,sleeplessness,hypersexu-
ality,and irritability and anger.Children presenting with
more subtle symptoms of anhedonia and fatigue are not
always as obvious in presentation to parents or teachers as
those presenting with such manic symptoms.Irritability,as
mentioned above,is also often mistaken as mania and not
recognized as a symptom of depression.Finally,in younger
children such depressive episodes are not as common as
for adolescents with BD,but depressive symptoms may
often intermingle with manic symptoms, and thus be
underidentified.Clinicians may benefit from carefully elic-
iting depressive symptomatology in any child with BD,and
recognizing any type of suicidal ideation,even passive,as
a red flag for a serious depressive episode.
Nonetheless, due to the morbidity and mortality of
depression in youth with BD,it is necessary to treat these
children. One may look to the treatment of bipolar
depression in adults for some guideposts,as this topic has
been more studied in adults.There exist many treatment
options for patients with bipolar depression.While anti-
depressants have historically been the first line of treat-
ment for bipolar depression,concern over the propensity
for antidepressants to cause manic switching or cycle
acceleration has led to questioning of this approach.
18 It
is becoming clear that overall,the addition of antidepres-
sants to mood stabilizers for adult bipolar depression
offers no greater benefit than placebo,
19 and up to 44%
of adults with BD have experienced a switch into mania
or a mixed episode with an antidepressant trial.
20Thus,
several expert consensuses have recommended nonanti-
depressant medications as first-line treatment for adults
with bipolar depression,including lithium,lamotrigine,
olanzapine-fluoxetine combination,
21 and quetiapine.
22
Other options showing some efficacy in controlled trials
include divalproex,olanzapine,and pramipexole.
23
Despite these adult data, it is still important to remem-
ber that children are distinct neurodevelopmentally,and
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Selected abbreviations and acronyms
BD bipolar disorder
CDRS-R Children’s Depression Rating Scale-Revised Version
MDD major depressive disorder
SSRI selective serotonin reuptake inhibitorso may not respond as adults do to psychotropic medica-
tions, both in positive and negative ways. Indeed, it
appears that youth, particularly peripubertal children,
may be more susceptible to deleterious effects of selec-
tive serotonin reuptake inhibitors (SSRIs) than adults.
In an analysis of an HMO database of 87 920 patients
aged 5 to 29 years old, children 10 to 14 years old were
at the highest risk of switching from a diagnosis of MDD
to BD after being prescribed an SSRI.
24 However,
despite case reports of SSRI-induced mania in depressed
children,
25,26 one study found no evidence retrospectively
that antidepressant exposure in depressed children led
to higher rates of mania than children without such
exposure.
27 It is possible that bipolar youth are more sus-
ceptible to AIM.In a retrospective chart review,42 chil-
dren with BD who were prescribed SSRIs were seven
times more likely to improve in depressive symptoms
than children with BD who were not prescribed any
other medication,
28 but three times more likely to expe-
rience a subsequent manic episode. Furthermore, in a
retrospective study of 54 children with BD, 50% had a
manic episode within 1 month of starting an SSRI, and
25% had new-onset suicidal ideation.
29 Thus, it is possi-
ble that bipolar youth may account for some of the con-
cerns regarding SSRIs and suicidality that eventually led
to the black-box warning on all antidepressants man-
dated by the US FDA.
30
Thus, alternative treatments need to be considered in
children and adolescents with BD,perhaps even more so
than for adults.While no placebo-controlled studies have
yet been reported in pediatric bipolar depression, two
prospective treatment studies in adolescents with bipo-
lar depression have been reported.Chang and colleagues
studied the effectiveness and tolerability of lamotrigine
as mono- or adjunctive therapy in an 8-week open-label
study of 20 adolescents with BD experiencing a depres-
sive episode.
31The authors reported statistically signifi-
cant improvement in depressive symptoms,as measured
by the Children’s Depression Rating Scale-Revised
Version (CDRS-R).
32 Sixty-three percent of subjects
were classified as responders, with at least a 50%
decrease in CDRS-R score between baseline and end
point,and 47% were considered remitters by virtue of a
score of 24 or less on the CDRS-R and a Clinician
Global Impression-Severity rating of “not ill”or “mildly
ill.” Additionally, 84% of subjects showed “much” or
“very much”improvement by the end of the study by the
Clinical Global Impression-Improvement scale.Despite
the historical risk of serious rash with lamotrigine,partic-
ularly in children,no serious rashes occurred in this study.
Furthermore,there was no significant weight gain.Patel
and colleagues
33 conducted a 6-week open-label study of
lithium monotherapy in 27 depressed adolescents with
bipolar I disorder.Forty-eight percent of subjects were
considered responders by a 50% reduction in CDRS-R
score from baseline to end point. Commonly reported
side effects were headaches (74%) and nausea/vomiting
(67%).Thus,while promising,these studies point to the
need for larger,placebo-controlled studies of these and
other agents (eg,quetiapine,bupropion) in youth with
bipolar depression.Another agent that might be studied
in this regard is omega-3 fatty acid supplements, given
some mild efficacy in preventing adult bipolar depres-
sion,and in treating adult bipolar depression.
34
Depressive symptoms
Even when youth with BD are not in full depressive
episodes,it is becoming clear that they often experience
subsyndromal depressive symptoms as well as mixed
states.Birmaher and colleagues studied 263 children and
adolescents with BD I, II, and not otherwise specified
(NOS) over 2 to 3 years.
35,36 Subjects were symptomatic
60% of the time,but only in full syndromal depressed or
manic episodes 22% of the time.Furthermore,fluctua-
tions in mood were very common. Children with BD
changed between mania and depression an average of 16
times per year,with 34.1% shifting polarity more than 20
times per year.
Because manic symptoms are often the first targeted
symptoms in youth with BD,these patients often experi-
ence residual or emergent depressive symptoms, even
with treatment.An older report found 3 out of 6 (50%)
of manic children placed on lithium to have a significant
worsening of depressive symptoms.
37 In a more recent
study of 100 manic adolescents treated prospectively with
lithium, mean HAM-D scores decreased overall from
12.63 to 6.74 over 4 weeks.
38 It is not reported how many
subjects had significant residual depressive symptoms at
the end of the study.However,having depressive symp-
toms at the start of the study did not predict whether or
not the subject responded to lithium by mania criteria.In
another open study,Kowatch and colleagues reported on
the naturalistic prospective treatment of 35 manic chil-
dren and adolescents who had previously been treated
with 6 weeks of monotherapy with either lithium, val-
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75proate, or carbamazepine.
39 Two subjects (5.7%) had a
depressive episode despite treatment with two concur-
rent mood stabilizers (lithium, divalproex, or carba-
mazepine).Antidepressants were subsequently added to
the medication regimens with reported good response.
Of 90 children and adolescents with BD treated openly
with divalproex and lithium combination therapy,none
continued to have significant depressive symptoms
requiring discontinuation from the study.
40
More recent large placebo-controlled studies offer some
insight into the natural course and treatment of depres-
sive symptoms in youth with BD.For example,olanzap-
ine was compared with placebo in a 3-week study of 158
youth with acute manic or mixed episodes.
41 Eight per-
cent of subjects on olanzapine and 14% of subjects on
placebo switched to a full depressive episode by the end
of the study. This was not a significant difference
between groups, and the change in depressive sympto-
matology, while not reported, was also not different
between groups.Thus, it would appear that at least for
the acute treatment of depressive symptoms in the con-
text of pediatric manic or mixed episodes,olanzapine is
not effective.
Similarly,in a study of divalproex versus placebo in 150
youth (10 to 17 years old) with manic or mixed episodes,
there was no difference in the amount of change in
CDRS-R scores between groups.
42 In a study of 116 sim-
ilarly diagnosed youth,oxcarbazepine resulted in a 7.9-
point decrease in CDRS-R score,versus 6.4 for placebo,
a nonsignificant decrease.
43Thus,as yet it does not appear
that these commonly used treatments for children with
BD result in effective changes in depressive symptoms.
Due to the predominance of subsyndromal depressive
symptoms in bipolar youth,it would be important to con-
duct studies specifically examining treatment of these
symptoms versus placebo.
First-episode bipolar depression
In a questionnaire of adults with BD, depressed mood
was the most common presenting symptom before the
onset of a full mood episode.
44The initial episode is com-
monly (>50%) depressive.
3 Furthermore,50% to 66% of
adults report onset of symptoms before the age of 18
years,with 28% occurring before 13 years.
2,3Therefore,
children with depression may be experiencing a first-
episode bipolar depression. Geller et al report 20% to
49% of children with MDD experience a full manic
episode by adulthood.
45A positive family history of BD
would seem to further elevate the risk of future mania in
a depressed child;however,the exact risk in these chil-
dren is not known.Given that many if not most of these
children will not ever experience mania,careful diagno-
sis and biological markers for predication would be
essential.Unfortunately,at this time there are no clear
biological markers that do predict such likelihood,
despite recent advances in neuroimaging and genetics
research.In the future,markers such as decreased amyg-
dalar volume, increased limbic activity, and the short
allele of the serotonin transporter gene,may all be com-
bined to calculate relative risk of BD development.
46
Until then we are left to rely on careful clinical assess-
ment and family history.
Proposed clinical clues of first episode bipolar depression
include an acute onset,psychosis,prominent irritability
and labile mood,and poor or brief hypomanic reactions
to antidepressants.
47 Furthermore, features of atypical
depression, including hypersomnia, hyperphagia, and
other neurovegetative symptoms,may indicate risk for
future manic episodes.
48
Despite the uncertainty of actual BD risk,early interven-
tions in youth with depression and family histories of BD
are beginning to be studied.Geller and colleagues per-
formed the first such study
49 in 30 prepubertal children,
all with MDD and family histories of mood disorder.
Forty percent had a parent with BD,40% had a more dis-
tant relative with BD,and 20% had a family history of
unipolar depression only.Subjects were randomized to
lithium or placebo,and after 6 weeks no differences were
found between the two groups in improvement in
depressive symptoms. The final Clinical Global
Assessment of Severity scores in both groups did
improve from baseline,but remained below 60,indicat-
ing continuing clinical problems.As there was a signifi-
cant distribution of subjects who responded well and sub-
jects who responded poorly,some subjects may have had
unique factors associated with response, but whether
family history was a factor is unknown. Nonetheless,
lithium may have limited efficacy in youth with depres-
sion at high risk for BD.
In another early intervention study,Chang and colleagues
investigated the effectiveness of open divalproex in 24
bipolar offspring with mood and/or disruptive behavioral
disorders.
50 None of the subjects,aged 7 to 17,had bipolar
I or II disorder,but all had at least some mild affective
symptoms as manifested by a minimum score of 12 on the
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Scale for Depression (HAM-D).Of these subjects,21%
(5) were diagnosed with MDD, and 8% (2) with dys-
thymia.Subjects were tapered off of any current medica-
tions,and then begun on divalproex monotherapy,even-
tually reaching a mean final dose of 821 mg/day (serum
level = 79.0+/-26.8 ug/mL).After 12 weeks,78% of sub-
jects were considered responders, having general
improvement in mood and functioning,with the majority
showing improvement by week 3. Both YMRS and
HAM-D scores decreased significantly compared with
baseline.Depressive symptoms appeared to resolve espe-
cially rapidly, with mean HAM-D scores achieving the
end point mean by week 1. This rate of response may
have been due to placebo response, receiving support
from an academic institution,being in a study,and having
regular visits to a physician. However, this placebo
response would have been carried throughout the 12
weeks of the study.Of note,6 out of 7 (86%) of subjects
with MDD or dysthymia were considered responders.
Again,caution should be applied to these results given the
small sample size and lack of a control arm.
Despite these promising findings regarding divalproex,
Findling and colleagues found divalproex to be no more
effective than placebo in preventing worsening of mood
symptoms in youth with cyclothymia or bipolar disorder
not otherwise specified who were bipolar offspring.
51 In
this study,56 subjects 5 to 17 years old were randomized
to divalproex or placebo and assessed over an acute 8-
week period, and then followed monthly for up to 5
years, until clinical intervention was needed for mood
symptoms.There was no difference between the treat-
ment arms in time to discontinuation from the study.
However,both groups did show significant improvement
in depressive and manic symptoms over time.Notably,
divalproex was superior to placebo in time to discontin-
uation in a subset of patients who had three or more first-
or second-degree relatives with an emotional and/or
behavioral problem.
52,53 It should also be noted that sub-
jects in this study differed from those in the study by
Chang and colleagues in that they had not had a past full
depressive episode,and they were required to have a past
significant 4-hour period of elation,indicating that they
may have had less symptoms of depression.Nonetheless,
there was no difference between divalproex and placebo
for efficacy regarding depressive symptoms.
Quetiapine would seem a good candidate for use in first-
episode bipolar depression, given its efficacy in adult
bipolar depression.
54 DelBello and colleagues
55 conducted
a 12-week study of open quetiapine for bipolar offspring
with mood disorders (mean age =14.7 years),that were
considered subsyndromal to full BD (no subjects had a
history of mania).11 (55%) had BD-NOS,3 had bipolar
II disorder,3 (11%) had dysthymia,2 cyclothymia,and 1
MDD.Thus,almost all subjects had a bipolar spectrum
disorder,and as such these subjects were farther along
the progression line for BD than the previously discussed
studies involving valproate.Quetiapine was begun at 100
mg/day,then increased every day up to 400 mg/day,with
flexible dosing thereafter to achieve 300-600 mg/day
based on clinical need.15 subjects completed the study,
and final mean dose was 460 mg/day.Response was con-
sidered a “1”or a “2”on the CGI-BP (Much or moder-
ate improvement in bipolar symptoms). After 1 week
there were 4 responders (25%),which grew to 81% by
week 12.Of note,the one subject with MDD was a non-
responder, but all three subjects with dysthymia were
responders.YMRS score decreased from 18.1 to 8.7,and
mean CDRS-R score decreased from 38.2 to 27.7.
Therefore, quetiapine may have clinical utility in this
population,but larger controlled studies are needed to
clarify its role in first episode bipolar depression in youth.
It should be remembered that these studies did not
address prevention of mania,as longer longitudinal stud-
ies are needed to address that issue. Agents such as
lithium,divalproex,and quetiapine may be efficacious in
decreasing depressive symptoms in these children at risk
for BD, but is unclear if they are more effective than
placebo or actually prevent or delay mania.In none of
these studies, however, did these agents precipitate
mania,so in this sense they may prove to be safer than
antidepressants in this population.As for other bipolar
depressed states,these and other agents deserve further
study in this population.
Psychotherapeutic/psychosocial 
interventions
Psychotherapy may prove to be an effective adjunctive or
alternate treatment in depressed youth with or at risk for
BD,as it may be more targeted than medications,without
the potential for physical or behavioral adverse effects.
Various psychotherapeutic approaches,including cogni-
tive-behavioral therapy (CBT),dialectical-behavioral ther-
apy (DBT) and family therapy,are beginning to demon-
strate efficacy in pediatric BD.In an open study of DBT
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cidal ideations and behaviors decreased significantly over
1 year.
56 In a small controlled study of CBT for adolescents
with BD,significant decreases in parent and child reported
depressive symptoms were reported in the CBT condition.
However,compared with control BD youth who did not
receive CBT,there were no differences in post-treatment
depression scores by clinician assessment.
57These individ-
ual therapy approaches show promise and should be stud-
ied in larger,controlled studies.
A recent study of family-focused therapy (FFT) in 58
adolescents with BD found that FFT was more effective
than “enhanced care (EC),”a series of psychoeducational
sessions.
58 Subjects receiving FFT recovered faster from
their baseline depressive symptoms than did subjects
receiving EC.While FFT did not more effectively pre-
vent relapse of depressive episodes, subjects receiving
FFT spent fewer weeks in depression than subjects in
EC.These novel approaches to prevention of depression
could be similarly applied to bipolar offspring.A modifi-
cation of FFT is now being studied for bipolar offspring
with MDD or BD-NOS.
59
Therefore,depression in the context of BD in youth may
be particularly responsive to psychotherapeutic interven-
tions,potentially more so than mania.Common themes
of these interventions are psychoeducation,behavioral
and cognitive interventions,including reducing stress and
improving coping strategies,and mood regulation tech-
niques.Future studies incorporating larger samples,with
youth with bipolar depression,depressive symptoms,or
unipolar depression at risk for BD would be highly illu-
minating to the field.
Conclusions
As the existence of BD in youth is becoming less contro-
versial,clinicians and researchers are now able to con-
centrate on understanding the full spectrum of symptoms
experienced by these patients,and researchers are able
to concentrate on all aspects of the illness, including
depressive symptomatology.It is clear that while mania
is impairing in this condition,depressive symptoms may
ultimately be just as if not more damaging,particularly
leading to suicidal thoughts and behaviors.Recognition
of depressive episodes in bipolar youth and in youth at
high risk for BD is essential for the purposes of early
intervention and prevention of progression of the disor-
der.Meanwhile,it is becoming clear that SSRIs have dan-
gerous potential in this population,while certain mood
stabilizers,antipsychotics,and psychotherapies may be
better alternatives.Treatment options are slowly growing
and future research will allow clinicians to more confi-
dently identify and treat depression in the context of
pediatric BD. ❏
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Desafíos en el diagnóstico y tratamiento de
la depresión bipolar pediátrica
En la última década ha existido un gran interés
público y académico acerca del diagnóstico y trata-
miento de los trastornos bipolares (TB) en niños y
adolescentes; esto ocurrió originalmente en los EE.
UU. y luego se extendió internacionalmente. 
Gran parte del interés en el TB pediátrico se ha con-
centrado exclusivamente en la manifestación maní-
aca de los grupos de menor edad. La depresión en
estos niños a menudo es pasada por alto, ya sea
como tópico o como una realidad clínica. Aunque
se está aclarando que los adultos con TB pasan la
mayor parte del tiempo sintomático con episodios
depresivos más que maníacos, poco se sabe acerca
de cómo experimentan los niños la depresión bipo-
lar. Sin embargo, los niños y adolescentes con TB
claramente sufren síntomas depresivos como tam-
bién episodios depresivos significativos; por lo que
es necesario que el reconocimiento y tratamiento
sean precoces. Esta revisión se orienta hacia el cono-
cimiento sobre la prevalencia, la presentación y el
tratamiento de los síntomas y episodios depresivos
en los jóvenes con TB, e incluye una discusión sobre
el reconocimiento y tratamiento de los episodios
depresivos que ocurren antes del primer episodio
maníaco. 
Remise en cause du diagnostic et du 
traitement de la dépression bipolaire chez
l’enfant
Ces 10 dernières années ont été le théâtre d’un
intérêt collectif et spéculatif croissant pour le dia-
gnostic et le traitement des troubles bipolaires (TB)
des enfants et des adolescents, à l’origine aux USA
puis dans le monde entier. Seules les manifestations
maniaques ont été jugées dignes d’intérêt dans les
TB des plus jeunes, chez qui la dépression est sou-
vent négligée, à la fois comme sujet et comme réa-
lité clinique. Alors qu’il est clairement reconnu que
les adultes ayant des TB passent plus de temps en
période dépressive qu’en période maniaque, l’ex-
périence pédiatrique en la matière est moins bien
connue. Les enfants et les adolescents présentant
des TB font cependant l’expérience de symptômes
dépressifs significatifs comme d’épisodes dépressifs
caractérisés, c’est pourquoi un diagnostic et un trai-
tement précoces sont nécessaires. Cet article pro-
pose une revue des données de prévalence, des
manifestations et du traitement des symptômes et
épisodes dépressifs chez les jeunes ayant des TB
ainsi qu’une discussion sur l’identification et le trai-
tement des épisodes dépressifs bipolaires interve-
nant avant le premier épisode maniaque.
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